Clinical Trials Sponsored by Ocala Oncology

Total 4531 results

ALX Oncology Inc.

Recruiting

A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

Bladder Cancer | Urothelial Carcinoma

United States
Children's Oncology Group

Not yet recruiting

A Study With DAY101 as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recurrent Langerhans Cell Histiocytosis | Refractory Langerhans Cell Histiocytosis
RS Oncology LLC

Recruiting

Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Mesothelioma | Malignant Pleural Mesothelioma | Pleural Effusion, Malignant | Mesotheliomas Pleural | Malignant Pleural Effusion | Mesothelioma; Lung

United Kingdom
Maastricht Radiation Oncology

Recruiting

Lung Cancer Organoids and Patient Derived Tumor Xenografts (Lung organoids)

Lung Cancer

Netherlands
Kura Oncology, Inc.

Recruiting

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

HNSCC

United States
Taiho Oncology, Inc.

Recruiting

A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer

Breast Cancer | Glioblastoma | Solid Tumor | Non-small Cell Lung Cancer

United States, France
CG Oncology, Inc.

Recruiting

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin (BOND-003)

Non Muscle Invasive Bladder Cancer | High-grade Ta/ T1 Papillary Disease Bladder Cancer

United States, Korea, Republic of, Taiwan, Japan, Australia
Maastricht Radiation Oncology

Recruiting

Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II Trial (IPON-1)

Carcinoma, Non-Small-Cell Lung

Netherlands
Celyad Oncology SA

Recruiting

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells (alloSHRINK)

Unresectable Metastatic Colorectal Cancer

Belgium, United States
VM Oncology, LLC

Recruiting

Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Sarcoma | Cervical Cancer | Breast Cancer | Adenoid Cystic Carcinoma | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Thymic Carcinoma | Lung Cancer | Mesothelioma | Bladder Cancer | Head and Neck Carcinoma | Uterine Cancer | Any Solid Tumors Progressed After a Prior Immunotherapy

United States, Puerto Rico
Mural Oncology, Inc

Active, not recruiting

Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3)

Advanced Solid Tumor

United States, Spain
CG Oncology, Inc.

Available

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Bladder Cancer | Urothelial Carcinoma | Urologic Cancer | Non-Muscle Invasive Bladder Cancer
Taiho Oncology, Inc.

Active, not recruiting

Futibatinib in Patients With Specific FGFR Aberrations

Advanced or Metastatic Solid Tumor | Advanced or Metastatic Gastric or Gastroesophageal Cancer | Myeloid or Lymphoid Neoplasms (MLN)

United States, Spain, Turkey, Hong Kong, Korea, Republic of, Belgium, Japan, Netherlands, France, Germany, Italy, Sweden, United Kingdom, Portugal, Singapore
Kura Oncology, Inc.

Available

Expanded Access to Tipifarnib

HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
Taiho Oncology, Inc.

Approved for marketing

Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Advanced Cholangiocarcinoma

United States
Mural Oncology, Inc

Completed

A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

Advanced Solid Tumors

Canada, Spain, United States, Australia, Belgium, Korea, Republic of, Poland
US Oncology Research

Active, not recruiting

MYLUNG Consortium Study Protocol 2 (MYLUNG)

Carcinoma, Non-Small-Cell Lung

United States
Rain Oncology Inc

Terminated

Milademetan in Advanced/Metastatic Solid Tumors

Melanoma | Sarcoma | Cervical Cancer | Testicular Germ Cell Tumor | Gastric Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Lung Adenocarcinoma | Solid Tumors | Pancreas Cancer | Head and Neck Carcinoma | Biliary Tract Cancer | Ovarian Carcinoma | Adrenocortical Carcinoma | Bladder Urothelial Carcinoma | Breast... and other conditions

United States
Rain Oncology Inc

Terminated

Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma (MANTRA)

Dedifferentiated Liposarcoma

United States, Spain, France, Korea, Republic of, Taiwan, Canada, Hong Kong, Austria, Germany, Belgium, Georgia, Ireland, Italy, Poland, United Kingdom
Maastricht Radiation Oncology

Withdrawn

Standard of Care Lifestyle Support for Stage III NSCLC Patients (PERCUSSION)

Non Small Cell Lung Cancer
Celyad Oncology SA

Active, not recruiting

Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma (IMMUNICY-1)

Relapse/Refractory Multiple Myeloma

Belgium, United States
Sierra Oncology, Inc.

Completed

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF (Simplify 2)

Primary Myelofibrosis (PMF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) | Post-polycythemia Vera (Post-PV)

United States, Canada, France, Italy, Germany, Spain, Israel, United Kingdom
Taiho Oncology, Inc.

Terminated

A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities

Advanced Solid Tumors With HER2 Abnormalities | Advanced Solid Tumors With HER3 Abnormalities

United States, Spain, France, United Kingdom
Rain Oncology Inc

Terminated

Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients (TH-4000)

NSCLC | Non-small Cell Lung Cancer | Non-squamous NSCLC

United States, Australia
Rain Oncology Inc

Terminated

Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin

Metastatic Head-and-neck Squamous-cell Carcinoma

United States, Australia
Taiho Oncology, Inc.

Completed

Evaluating Patients With Varying Degrees of Renal Function

Renal Impairment

United States
Maastricht Radiation Oncology

Completed

Immune Profiling After HDR in Local Relapsed Prostate Cancer (PRIMUS)

Prostate Cancer | PD-L1

Netherlands
Taiho Oncology, Inc.

Completed

Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer

Refractory Metastatic Gastric Cancer

France, United States, Spain, United Kingdom, Germany, Ireland, Japan, Belgium, Italy, Turkey, Belarus, Israel, Portugal, Russian Federation, Czechia, Poland, Canada, Romania
Taiho Oncology, Inc.

Terminated

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

Multiple Myeloma | NonHodgkin Lymphoma

United States
Pantarhei Oncology B.V.

Completed

Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer

Breast Neoplasms

Germany
Pantarhei Oncology B.V.

Completed

Evaluation of Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist.

Prostatic Neoplasm

Netherlands
Kura Oncology, Inc.

Completed

Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia (CMML/AML)

Leukemia, Myelomonocytic, Chronic

United States
CG Oncology, Inc.

Completed

Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure (BOND2)

Bladder Cancer

United States
Clovis Oncology, Inc.

Terminated

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

Locally Advanced or Metastatic Non Small Cell Lung Cancer

United States, Australia, France, Poland
Taiho Oncology, Inc.

Completed

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies (RECOURSE)

Colorectal Cancer

United States, Spain, United Kingdom, Australia, Sweden, Belgium, France, Ireland, Germany, Austria, Japan, Italy, Czechia
Maastricht Radiation Oncology

Completed

The Addition of Chloroquine to Chemoradiation for Glioblastoma (CHLOROBRAIN)

Glioblastoma Multiforme

Netherlands
Celyad Oncology SA

Unknown

A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK)

Acute Myeloid Leukemia/Myelodysplastic Syndrome | Multiple Myeloma (MM)

United States, Belgium
Maastricht Radiation Oncology

Completed

BioXmark, Rectal Feasibility Trial

Rectal Cancer

Netherlands
IGF Oncology, LLC

Completed

Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R

Melanoma | Breast Cancer | Brain Cancer | Head and Neck Cancers | Gastrointestinal Cancers | Gynecologic Cancers | Genitourinary Cancers | Thoracic Cancers

United States
Clovis Oncology, Inc.

Terminated

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Non-small Cell Lung Cancer

Korea, Republic of, United States, France, Germany, Netherlands, Australia, Spain, Taiwan, United Kingdom, Italy
Clovis Oncology, Inc.

Terminated

A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

Small Cell Lung Cancer | Non-Small Cell Lung Cancer | NSCLC | Lung Cancer | Metastatic Lung Cancer | SCLC | Stage IV Lung Cancer | Advanced Lung Cancer | Squamous Non-Small Cell Lung Cancer

United States, Italy, Germany, France, Spain
Inivata
Vector Oncology

Completed

Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing

Non-Small Cell Lung Cancer

United States
Maastricht Radiation Oncology

Completed

Predicting Outcome in Cervix Carcinoma: a Prospective Study (POCER)

Cervical Cancer

Netherlands, South Africa
Spirita Oncology, LLC

Terminated

A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations

AML | MDS | CMML

United States
Maastricht Radiation Oncology

Terminated

Tumor Hypoxia With HX4 PET in Several Diseases (HX4 SD)

Prostatic Neoplasms | Esophageal Neoplasms | Rectal Neoplasms | Brain Neoplasm, Primary | Neoplasm Metastases, Brain

Netherlands
Maastricht Radiation Oncology

Terminated

PET CT With HX4 in Cervix Cancer (HX4-cervix)

Cervix Cancer

Netherlands
Sierra Oncology, Inc.

Completed

Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Primary Myelofibrosis | Post-Polycythemia Vera | Post-Essential Thrombocythemia Myelofibrosis

United States, Canada
Sierra Oncology, Inc.

Completed

Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, Canada, Australia
Sierra Oncology, Inc.

Terminated

Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer

United States
Maastricht Radiation Oncology

Completed

Radiomics for Prediction of Survival in GBM (Radiomics)

Glioma | Glioblastoma | Astrocytoma

Netherlands

Clinical Trials Sponsored by Ocala Oncology

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations